Literature DB >> 31644322

Morphologic Spectrum of Neuroendocrine Tumors of the Prostate: An Updated Review.

Jing Hu1, Bo Han1, Jiaoti Huang1.   

Abstract

CONTEXT.—: The incidence of neuroendocrine tumors of the prostate increases after hormonal therapy. Neuroendocrine tumors possess a broad spectrum of morphologic features and pose challenges in the pathologic diagnosis and clinical management of patients. OBJECTIVE.—: To present a brief updated summary of neuroendocrine tumors of the prostate with an overview of their histopathologic and immunohistochemical profiles and differential diagnoses. DATA SOURCES.—: Literature review, personal experience in the daily practice of pathologic diagnosis, and laboratory research. CONCLUSIONS.—: Our understanding of neuroendocrine tumors of the prostate classification and diagnosis continues to evolve. These advances benefit the risk stratification and management of prostate cancer.

Entities:  

Year:  2019        PMID: 31644322     DOI: 10.5858/arpa.2019-0434-RA

Source DB:  PubMed          Journal:  Arch Pathol Lab Med        ISSN: 0003-9985            Impact factor:   5.534


  8 in total

1.  An algorithmic approach utilizing CK7, TTF1, beta-catenin, CDX2, and SSTR2A can help differentiate between gastrointestinal and pulmonary neuroendocrine carcinomas.

Authors:  Sanhong Yu; Jason L Hornick; Raul S Gonzalez
Journal:  Virchows Arch       Date:  2021-03-17       Impact factor: 4.064

Review 2.  Imaging of neuroendocrine neoplasms of the male GU tract.

Authors:  Kedar G Sharbidre; Ajaykumar C Morani; Mohd Zahid; Priya Bhosale; Chandana Lall; Isaac R Francis; Sadhna Verma
Journal:  Abdom Radiol (NY)       Date:  2022-04-12

3.  Circulating Tumor Cell Chromosomal Instability and Neuroendocrine Phenotype by Immunomorphology and Poor Outcomes in Men with mCRPC Treated with Abiraterone or Enzalutamide.

Authors:  Landon C Brown; Susan Halabi; Joseph D Schonhoft; Qian Yang; Jun Luo; David M Nanus; Paraskevi Giannakakou; Russell Z Szmulewitz; Daniel C Danila; Ethan S Barnett; Emily A Carbone; Jimmy L Zhao; Patrick Healy; Monika Anand; Audrey Gill; Adam Jendrisak; William R Berry; Santosh Gupta; Simon G Gregory; Richard Wenstrup; Emmanuel S Antonarakis; Daniel J George; Howard I Scher; Andrew J Armstrong
Journal:  Clin Cancer Res       Date:  2021-04-05       Impact factor: 13.801

4.  Treatment-Emergent Neuroendocrine Prostate Cancer: A Clinicopathological and Immunohistochemical Analysis of 94 Cases.

Authors:  Qingfu Zhang; Yunan Han; Yao Zhang; Dan Liu; Jian Ming; Bo Huang; Xueshan Qiu
Journal:  Front Oncol       Date:  2021-02-01       Impact factor: 6.244

5.  Long response duration to pembrolizumab in metastatic, castration-resistant prostate cancer with microsatellite instability-high and neuroendocrine differentiation: A case report.

Authors:  Tsukasa Yoshida; Hiroshi Yaegashi; Ren Toriumi; Suguru Kadomoto; Hiroaki Iwamoto; Kouji Izumi; Yoshifumi Kadono; Hiroko Ikeda; Atsushi Mizokami
Journal:  Front Oncol       Date:  2022-09-16       Impact factor: 5.738

6.  Conditionally Reprogrammed Cells from Patient-Derived Xenograft to Model Neuroendocrine Prostate Cancer Development.

Authors:  Xinpei Ci; Jun Hao; Xin Dong; Hui Xue; Rebecca Wu; Stephen Yiu Chuen Choi; Anne M Haegert; Colin C Collins; Xuefeng Liu; Dong Lin; Yuzhuo Wang
Journal:  Cells       Date:  2020-06-04       Impact factor: 6.600

7.  DNA Polymerase Alpha Subunit B Is a Binding Protein for Erlotinib Resistance in Non-Small Cell Lung Cancer.

Authors:  Tae Young Kim; Eun Sun Ji; Ju Yeon Lee; Jin Young Kim; Jong Shin Yoo; A Marcell Szasz; Balazs Dome; Gyorgy Marko-Varga; Ho Jeong Kwon
Journal:  Cancers (Basel)       Date:  2020-09-13       Impact factor: 6.639

8.  Chromatin-directed proteomics-identified network of endogenous androgen receptor in prostate cancer cells.

Authors:  Kaisa-Mari Launonen; Ville Paakinaho; Gianluca Sigismondo; Marjo Malinen; Reijo Sironen; Jaana M Hartikainen; Hanna Laakso; Tapio Visakorpi; Jeroen Krijgsveld; Einari A Niskanen; Jorma J Palvimo
Journal:  Oncogene       Date:  2021-06-14       Impact factor: 9.867

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.